Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 18/20 | 0.56 |
| ▸ | SMARCA2 | P51531 | 16/20 | 0.56 |
| ▸ | SMARCA4 | P51532 | 16/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 7/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23301224 | 0.90 | PBRM1 (0.52) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL29943128 | 0.88 | CKS1B (0.42) | PBRM1SMARCA2SMARCA4 | |
| SCHEMBL23772838 | 0.87 | PBRM1 (0.67) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL29943338 | 0.86 | PBRM1 (0.76) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL23301547 | 0.86 | PBRM1 (0.76) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL23301270 | 0.84 | PBRM1 (0.56) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL30148023 | 0.84 | PBRM1 (0.56) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL28947537 | 0.84 | PBRM1 (0.55) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL29942840 | 0.84 | PBRM1 (0.55) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| Hydrochloric Acid SCHEMBL29943400 | 0.84 | PBRM1 (0.55) | PBRM1SMARCA2SMARCA4NR1I2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230024096-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | C4 THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| EP-4051674-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2022-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024096-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | SMARCC1, SMARCC2, SMARCA2 | PBRM1 99/4885SMARCA2 3/4885SMARCA4 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.